WHAT IS CLAIMED IS:

1. A pharmacological composition comprising:

(A) at least one biologically-active agent; and

(B) at least one carrier compound having the formula

2-HO-Ar-CONR^8-R^7-COOH

wherein Ar is a substituted or unsubstituted phenyl or naphthyl;

R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_{20} alkenyl, phenyl, naphthyl, (C_1 to C_{10} alkyl) phenyl, (C_1 to C_{10} alkenyl) phenyl, (C_1 to C_{10} alkyl) naphthyl, (C_1 to C_{10} alkenyl) naphthyl, phenyl (C_1 to C_{10} alkyl), phenyl (C_1 to C_{10} alkenyl), naphthyl (C_1 to C_{10} alkyl), and naphthyl (C_1 to C_{10} alkenyl);

R^8 is selected from the group consisting of hydrogen, C_1 to C_4 alkyl, C_1 to C_4 alkenylC_1 to C_4 alkenyl, hydroxy, and C_1 to C_4 alkoxy;

R^8 is optionally substituted with C_1 to C_4 alkyl, C_1 to C_4 alkenyl, C_1 to C_4 alkoxy, -OH, -SH and -CO_2R^9 or any combination thereof;

R^9 is hydrogen, C_1 to C_4 alkyl or C_1 to C_4 alkenyl;

R^7 is optionally interrupted by oxygen, nitrogen, sulfur or any combination thereof;

with the proviso that the compounds are not substituted with an amino group in the position alpha to the acid group;

or salts thereof.

2. The composition according to claim 1, wherein said biologically-active agent comprises at least one peptide, mucopolysaccharide, carbohydrate, or lipid.

3. The composition according to claim 2, wherein said biologically active agent is selected from the group consisting of human growth hormone, bovine growth hormone, growth hormone-releasing hormone, an interferon, interleukin-II, insulin,

heparin, calcitonin, erythropoietin, atrial naturetic factor, an antigen, a monoclonal antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone, oxytocin, vasopressin, cromolyn sodium, vancomycin, parathyroid hormone, desferrioxamine (DFO), or any combination thereof.

4. The composition according to claim 2, wherein said biologically-active agent comprises an interferon, interleukin-II, insulin, heparin, calcitonin, oxytosin, vasopressin, vancomycin, DFSO and combinations thereof.

5. The composition according to claim 4, wherein said biologically-active agent comprises calcitonin.

6. The composition according to claim 1, wherein R^6 is selected from the group consisting of C_4 to C_{20} alkyl and C_4 to C_{20} alkenyl.

7. The composition according to claim 1, wherein R^6 is selected from the group consisting of C_5 to C_{20} alkyl and C_5 to C_{20} alkenyl.

8. The composition according to claim 1 wherein the carrier has the formula



or salts thereof.

9. The composition according to claim 1 wherein said carrier is a compound selected from the group consisting of



XIX



XXII

XXXVII



XXXVIII



XXIX

9  XXX

10  XXXI

11  XXXV

12  CIII

E-534

13  CV

E-463



E-592

CVI



E-595

CVII



E-583

CX

or salts thereof.

10. The composition according to claim 1 wherein the carrier is a compound selected from the group consisting of



A

Compound	n	m	X
LII	1	0	2-OH
LIII	3	0	2,6-dihydroxy
LIV	2	0	2-OH
LVI	2	0	2,6-dihydroxy

or salts thereof.

11. The composition according to claim 1 wherein the carrier is a compound selected from the group consisting of



G

Compound	n	m	X
CXI	6	0	2-OH
CXIX	9	0	2-OH

or salts thereof.

12. The composition according to claim 1, wherein said carrier has the formula



XIX

or salts thereof.

13. The composition according to claim 1, wherein said The composition according to claim 1 wherein the carrier has the formula



XXXI

or salts thereof.

14. A dosage unit form comprising

(A) a pharmacological composition according to claim 1; and

(B) (a) an excipient,

(b) a diluent,

(c) a disintegrant,

(d) a lubricant,

(e) a plasticizer,

(f) a colorant,

(g) a dosing vehicle, or

(h) any combination thereof.

15. A dosage unit form according to claim 14, comprising a tablet, a capsule, or a liquid.

16. A dosage unit form according to claim 15, wherein said dosing vehicle is selected from the group consisting of water, 1,2-propane diol, ethanol or any combination thereof.

17. A method for administering a biologically-active agent to a mammal in need of said agent, said method comprising administering orally to said mammal a composition as defined in claim 1.

18. A method for preparing a pharmacological composition, said method comprising mixing:

(A) at least one biologically-active agent;

(B) at least one carrier compound according to claim 1; and

(C) optionally a dosing vehicle.

19. A method for administering a biologically-active agent to a animal in need of said agent, said method comprising administering orally to said mammal a composition as defined in claim 1.